An International Journal Clinical Rhinology

Register      Login

VOLUME 2 , ISSUE 3 ( September-December, 2009 ) > List of Articles

RESEARCH ARTICLE

Invasive Fungal Rhinosinusitis: Our Experience

Kapil Dua, H Chopra, Neha Chopra, Sanjeev Puri, Vikrant Mittal

Keywords : Immunocompromised,mucormycosis,aspergillosis

Citation Information : Dua K, Chopra H, Chopra N, Puri S, Mittal V. Invasive Fungal Rhinosinusitis: Our Experience. Clin Rhinol An Int J 2009; 2 (3):21-26.

DOI: 10.5005/jp-journals-10013-1005

Published Online: 01-12-2009

Copyright Statement:  Copyright © 2009; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Opportunistic fungal infections in immunocompromised patients are associated with a high mortality rate. Endemic mycoses are often asymptomatic, but in appropriate hosts, fungi can cause severe and even fatal infection. Facial pain in an immunocompromised patient may signify invasive fungal sinusitis. Treatment with antifungal agents needs to be individualized according to factors such as the type of fungus, presence of renal failure, or pregnancy. Combining antifungal agents or addition of other approaches, such as surgical debridement or steps to control intracranial pressure, may be needed for adequate treatment of certain types of fungal infections.


PDF Share
  1. Fulminant aspergillosis of the nose and paranasal sinuses: A new clinical entity. Laryngoscope 1980;90:748-54.
  2. Primary aspergillosis of the nose and paranasal sinuses and associated areas. Laryngoscope 1965;75:768-73.
  3. Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol Head Neck Surg 1992;107:745-50.
  4. The spectrum of orbital aspergillosis: A clinicopathological review. Surv Ophthalmol 1996;41:142-54.
  5. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
  6. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71.
  7. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, n Engl J Med 2002;347;408-15.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.